Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Order Online! Now! Get your $50 coupon for online order.
Order Online! Now! Get your $50 coupon for online order.
Our limited edition HOLIDAYS LLAMA is here! Place any order now to recieve one!
Earn Loyalty Rewards! Up to $155 Amazon Gift Card
Time Limited Offer: Welcome Gift for New Customers !
Time Limited Offer: Welcome Gift for New Customers !
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 44.6 kDa.
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
Lyophilized from 0.22 μm filtered solution in PBS, 0.2% BSA, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
5e5 of anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HP2H5) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).
5e5 of PBMCs were stained with PE-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HP2H5) and anti-CD3 antibody, washed and then analyzed with FACS. FITC signal was used to evaluate the expression of CD3+ T cells in PBMCs, and PE signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $350.00
Price(USD) : $2180.00
ACROBiosystems offers a wide selection of Matrigengel basement membrane extracts. Different versions – including phenol red-free, high concentration, iPSC culturing, organoid culturing – are all available for your specific needs to support 3D cell culture!
ComboX is a new brand of ACROBiosystems. ComboX products include our Streptavidin series products, coated plates, isotype controls for antibody and fusion protein drug research, and general-purpose antibodies.
To enable antibody characterization methodsACROBiosystems has developed a series of enzymes.such as ldeS, SpeB, EndoH, and Endo S proteases, toassist with the characterization of antibodies and theirrelated post-translational modifications (PTMs)
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro is ACROBiosystems brand focused on neuroscience research, providing high-quality important proteins including therapeutic and diagnostic research proteins, PFFs and recombinant neuro factors, etc. to advance neuroscience research.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tisagenlecleucel | CART-019; CTL-019; CART-19; LG-740 | Approved | Novartis Pharma Ag, University Of Pennsylvania | Kymriah | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Novartis Pharmaceuticals Corp | 2017-08-30 | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic | Details |
Loncastuximab tesirine | ADCT-402 | Approved | Adc Therapeutics Sa | Lonca, ZYNLONTA | United States | Lymphoma, Large B-Cell, Diffuse | Adc Therapeutics Sa | 2021-04-23 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoproliferative Disorders; Lymphoma; Waldenstrom Macroglobulinemia; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Blinatumomab | MEDI-538; MT-103; BiTE-MT-103; bscCD19xCD3; AMG-103 | Approved | Amgen Inc | Blincyto, 倍利妥 | United States | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Amgen Inc | 2014-12-03 | Lymphoma, B-Cell; Leukemia; Neoplasm, Residual; Leukemia, Myelogenous, Chronic; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Philadelphia Chromosome; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Tafasitamab | XENP-5574; MOR-00208; XmAb-5574; MOR-208 | Approved | Xencor Inc | MONJUVI, Minjuvi | United States | Lymphoma, Large B-Cell, Diffuse | Morphosys Us Inc | 2020-07-31 | Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Lisocabtagene maraleucel | Liso-Cel; JCAR-017 | Approved | Fred Hutchinson Cancer Research Center, Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute | Breyanzi | United States | Lymphoma, Large B-Cell, Diffuse | Bristol-Myers Squibb Company | 2021-02-05 | Lymphoma, B-Cell; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Immune System Diseases; Mediastinal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Inebilizumab | VIB-0551; 16C4-aFuc; MEDI-551; MT-0551 | Approved | Duke University, Horizon Therapeutics PLC | Uplinza, Uplizna, ユプリズナ | United States | Neuromyelitis Optica | Viela Bio Inc | 2020-06-11 | Myasthenia Gravis; Hematologic Neoplasms; Lymphoma, B-Cell; Rejection of renal transplantation; Immunoglobulin G4-Related Disease; Scleroderma, Systemic; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Multiple Sclerosis; Neuromyelitis Optica; Encephalitis; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Brexucabtagene autoleucel | KTE-X19; FKC-889 | Approved | Kite Pharma Inc, Gilead Sciences Inc | Tecartus | United States | Lymphoma, Mantle-Cell | Kite Pharma Inc | 2020-07-24 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Axicabtagene ciloleucel | FKC-876; KTE-C19; KTE C19 | Approved | Cabaret Biotech, Gilead Sciences Inc | Yescarta, 奕凯达 | United States | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Kite Pharma Eu Bv | 2017-10-18 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin | Details |
Relmacabtagene autoleucel | JWCAR-029 | Approved | Suzhou Yaomingjunuo Biotechnology Co Ltd | 倍诺达, Carteyva | Mainland China | Lymphoma, Large B-Cell, Diffuse | Jw Therapeutics (Shanghai) Co Ltd | 2021-09-01 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
4G7SDIE | Clinical | Synimmune Gmbh, The University Of Tubingen | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Fully human anti CD19 CAR-T Cell Therapy (University Hospitals Cleveland Medical Center) | Phase 1 Clinical | University Hospitals Cleveland Medical Center | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Leukemia; Lymphoma | Details | |
Anti-CD22/CD19 monoclonal antibody-toxin conjugate | Phase 1 Clinical | The University Of Texas Southwestern Medical Center | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) | Phase 2 Clinical | Southwest Hospital Chongqing | Lymphoma, Large B-Cell, Diffuse | Details | |
aCD19z | aCD19z | Phase 1 Clinical | Christie Hospital Nhs Foundation Trust | Lymphoma, Non-Hodgkin | Details |
PTG-01 | PTG-01 | Phase 1 Clinical | Protheragen | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
pCAR-19B | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
H-31970-SAGAN | H-31970-SAGAN | Phase 1 Clinical | Baylor College Of Medicine | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19 CAR T-cell therapy (Sheba Medical Center) | Phase 3 Clinical | Chaim Sheba Medical Center At Tel Hashomer | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details | |
Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-19 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell | Details |
CAR-20-19-22 | CAR-20-19-22 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
TC-110 | TC-110 | Phase 2 Clinical | Tcr2 Therapeutics Inc | Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin | Details |
Zamtocabtagene autoleucel | MB-CART2019.1 | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, Large B-Cell, Diffuse | Details |
GC-022 | GC-022; GC-022F | Phase 2 Clinical | Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
CD19-CART (Unicar-Therapy Bio-medicine Technology) | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) | Phase 2 Clinical | Shanghai Ultra-T Immune Therapeutics Co LTD | Lymphoma, B-Cell; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
CD19 CAR-T (HuaDao CAR-Tcell) | Phase 1 Clinical | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | ||
CD19/CD20 CAR-T Cell Therapy (PersonGen) | Phase 1 Clinical | Persongen Biotherapeutics | Details | ||
CD19-CART (Express 4-1BB, Unicar-Therapy Bio-medicine Technology) | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 universal CAR-T cell therapy (Chongqing Xinqiao Hospital) | Phase 1 Clinical | Xinqiao Hospital, Army Medical University | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) | Phase 2 Clinical | Shanghai Cellular Biopharmaceutical Group Ltd | Lymphoma, B-Cell | Details | |
Anti-BCMA/CD19 CAR-T Therapy(University College London) | Phase 1 Clinical | University College London | Multiple Myeloma | Details | |
BCN-CP01 | BCN-CP01; BCN CP01; BCN-CP-01 | Phase 2 Clinical | CellPoint BV | Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research) | Clinical | Leidos | Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD19 CAR T-cell therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Lymphoma, B-Cell | Details | |
MB-CART19.1 (Miltenyi Biotec) | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
XYF19 CAR-T Cell Therapy | XYF-19 | Phase 1 Clinical | Guangzhou Yinming Biomedical Technology Co Ltd, Xi'An Yufan Biotechnology Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
CD19 chimeric antigen receptor T cell therapy (Takara Bio) | TBI-1501 | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center, Takara Bio Inc | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh | Primary Immunodeficiency Diseases; Female Urogenital Diseases; Inflammation | Details | |
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Multiple Myeloma; Lupus Erythematosus, Systemic | Details | |
Virus-specific-CD19.CAR | Phase 1 Clinical | Baylor College Of Medicine | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD19 CAR T-cell therapy (University College London) | 4G7-CARD | Phase 1 Clinical | University College London | Lymphoma | Details |
Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing) | Phase 2 Clinical | Southwest Hospital Chongqing | Lymphoma, Large B-Cell, Diffuse | Details | |
CD19.CAR-VST | CD19.CAR-VST | Phase 1 Clinical | Baylor College Of Medicine | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
C-CAR011 | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma | Details | |
Anti-human CD19-CD22 T cell therapy | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
JCAR-014 | JCAR-014 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Juno Therapeutics Inc | Leukemia; Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Candidiasis; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD19-CAR(The University Of Texas MD Anderson Cancer Center) | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Leukemia; Lymphoma | Details | |
PCAR-019 (Anke Biotechnology) | Phase 1 Clinical | Anhui Anke Biotechnology (Group) Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Leukemia, Prolymphocytic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary mediastinal B cell lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details | |
Evoncabtagene pazurgedleucel | CTX-110 | Phase 1 Clinical | Crispr Therapeutics Ag | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
C-CAR039 | EXP-039; C-CAR039; C-CAR-039 | Phase 1 Clinical | Cellular Biomedicine Group Ltd | Lymphoma, Non-Hodgkin | Details |
CD19-targeted chimeric antigen receptor T-cell(Pell Bio-Med Technology) | PL-001 | Phase 2 Clinical | Pell Bio-Med Technology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma | Details |
YTB-323 | YTB-323 | Phase 2 Clinical | Novartis Pharma Ag | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
A-319 | A-319 | Phase 1 Clinical | Evive Biotech Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR CD19/79b | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell | Details |
ARI-0001 | IMN-003A; IMN-003-A; ARI-0001 | Phase 2 Clinical | Hospital Clínic De Barcelona, Institut D'Investigacions Biomèdiques August Pi I Sunyer | Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CB-010 | Phase 1 Clinical | Caribou Biosciences Inc | Lymphoma, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin | Details | |
CD19 CAR-T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Leukemia; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19/CD22 CAR-T cell therapy (Federal Research Institute of Pediatric Hematology, Oncology and Immunology) | Phase 2 Clinical | Federal Research Institute of Pediatric Hematology Oncology and Immunology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma | Details | |
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) | Phase 1 Clinical | Stanford University, Orca Biosystems Inc | Leukemia, Myelogenous, Chronic; Neoplasm, Residual; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid) | Phase 2 Clinical | Wuhan Bio-Raid Biotechnology | Hematologic Diseases; Lymphoma, B-Cell | Details | |
Anti-CD19 CAR-T cell therapy (Uppsala University) | Phase 2 Clinical | Uppsala University | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
CD19-CD123 cCAR T-cells Therapy(iCell Gene Therapeutics) | ICG140 | iCell Gene Therapeutics LLC | Details | ||
HuCART19 | Phase 2 Clinical | National Cancer Institute, Kite Pharma | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
IM19CAR-T | Phase 2 Clinical | Beijing Yimiao Medical Technology Co Ltd | Hematologic Neoplasms; Leukemia; Neoplasms; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma | Details | |
CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing) | Phase 2 Clinical | Xuanwu Hospital Of Capital Medical University | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19-CAR T cells (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Leukemia | Details | |
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering) | Phase 1 Clinical | Nagoya University, Shinshu University | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies) | PZ-01 | Clinical | Pinze Lifetechnology Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
MCM-998 | MCM-998; LXG-250 | Phase 1 Clinical | Novartis Pharma Ag | Multiple Myeloma | Details |
CLIC-1901 (Ottawa Hospital Research Institute) | CLIC-1901 | Phase 2 Clinical | Ottawa Hospital Research Institute | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19 CAR-Engineered NK Cells therapy (Simnova) | CAR-NK-CD19 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) | ICTCAR-014 | Phase 2 Clinical | Innovative Cellular Therapeutics Co Ltd | Lymphoma, Non-Hodgkin | Details |
CTA-101 | CTA-101 | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Leukemia, Lymphoid; Central Nervous System Neoplasms | Details | |
1928-zT-2 (Guangzhou Institutes of Biomedicine and Health) | Phase 1 Clinical | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR T-cell therapy (Hrain Biotechnology) | Phase 2 Clinical | Shanghai Zhongshan Hospital, Hrain Biotechnology Co Ltd | Candidiasis, Vulvovaginal; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
TanCART19/20 | Phase 1 Clinical | Pla General Hospital | Neuromyelitis Optica | Details | |
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) | 4SCAR19/22 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) | Phase 1 Clinical | First Affiliated Hospital Of Zhejiang University | Lymphoma, Large B-Cell, Diffuse | Details | |
NCAR19-T | Phase 2 Clinical | Second Military Medical University Of Chinese People'S Liberation Army | Lymphoma, B-Cell | Details | |
α/β CD3+/CD19+ cell depleted stem cell therapy (Mitchell Cairo) | Phase 2 Clinical | New York Medical College | Leukemia; Anemia; Thalassemia; Hodgkin Disease; Anemia, Aplastic; Lymphoma, Non-Hodgkin; Thrombocytopenia; Kostmann Syndrome; Anemia, Sickle Cell | Details | |
TNB-486 | TNB-486 | Phase 1 Clinical | Teneobio Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology) | SENL-B19 | Phase 2 Clinical | Hebei Senlang Biological Technology Co Ltd | Lymphoma, B-Cell; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma | Details |
Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine) | yinnuokati-19 | Phase 2 Clinical | Dongguan People'S Hospital, Shenzhen Institute For Innovation & Translational Medicine | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Nephritis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
IKS-03 | IKS-03 | Phase 1 Clinical | Iksuda Therapeutics | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell | Details |
Anti-CD19 CAR T-cell therapy (Nanjing Medical University) | XLCART-001 | Phase 2 Clinical | Nanjing Medical University | Lymphoma, B-Cell | Details |
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) | Phase 1 Clinical | Tianjin Mycure Medical Technology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
3rd-gen-CD19-CAR | 3rd-gen-CD19-CAR | Phase 2 Clinical | Bluebird Bio Inc | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
4-1BBz CD19-Her2tG (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Neoplasms; Lymphoma | Details | |
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell | Details | |
Allogenic Anti-CD19 gamma delta CAR-T cell therapy(PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, Non-Hodgkin | Details | |
Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals) | BPX-401 | Phase 2 Clinical | Bellicum Pharmaceuticals Inc, Ospedale Pediatrico Bambino Gesu | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details |
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19.CAR T Cells (Heidelberg University Hospital) | Phase 2 Clinical | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details | ||
Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research) | WZTL002-1 | Phase 1 Clinical | The Malaghan Institute Of Medical Research | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin | Details |
ISIKOK-19 | ISIKOK-19 | Phase 2 Clinical | Acibadem University | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
RG-6333 | RO-7443904 | Phase 1 Clinical | F. Hoffmann-La Roche Ag | Lymphoma, Non-Hodgkin | Details |
PBLTT52CAR19 | Phase 1 Clinical | Great Ormond Street Hospital For Children Nhs Foundation Trust | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center | Lymphoma, Non-Hodgkin | Details | |
KYV-101 | KYV-101 | Phase 1 Clinical | National Institutes Of Health, Kyverna Therapeutics Inc | Lupus Nephritis | Details |
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) | Phase 1 Clinical | University Of Colorado, Denver, Usa | Lymphoma, Non-Hodgkin | Details | |
K-193 | K-193 | Phase 1 Clinical | Beijing Lvzhu Biological Technology Co Ltd | Lymphoma, B-Cell | Details |
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | Phase 1 Clinical | The First Affiliated Hospital Of Nanchang University | Multiple Myeloma | Details | |
CD19-CAR-T2 cell therapy (Nanfang Hospital of Southern Medical University) | Phase 2 Clinical | Nanfang Hospital Of Southern Medical University | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Biphenotypic, Acute | Details | |
CD19-STAR-T cell therapy (China Immunotech Co Ltd) | Phase 1 Clinical | Hebei Yanda Hospital, China Immunotech Co Ltd | Lymphoma, B-Cell | Details | |
bispecific CD19/CD22 CAR T-cell therapy (University of Colorado) | Phase 1 Clinical | University Of Colorado | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
Anti-CD19 UCAR-NK cells(920th Hospital of Joint Logistics Support Force of People's Liberation Army of China) | Phase 2 Clinical | The 920th Hospital Of Joint Logistics Support Force Of PLA | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
CTA-30X | CTA-30X; CTA30X | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19/CD22-Dual-STAR-T cell therapy (Hebei Yanda Ludaopei Hospital) | Phase 1 Clinical | Hebei Yanda Ludaopei Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
Human CD19 Targeted DASH CAR-T Cells (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
ET190L1-ARTEMIS T cells (Eureka Therapeutics) | ET190L1-ARTEMI; ET-190; ET190L1; ET190 | Phase 1 Clinical | Eureka Therapeutics Inc | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
GB5005 chimeric antigen receptor T cell therapy (Genbase) | GB-5005 | Phase 1 Clinical | Shanghai Genbase Biotechnology Co Ltd, Shanghai Genechem Co Ltd | Leukemia, B-Cell | Details |
SNUH-CD19-CAR-T Cell Therapy | SNUH-CD19-CAR-T | Phase 1 Clinical | Seoul National University Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
MC-19PD1 CAR-T cell therapy (Peking University) | Phase 1 Clinical | Peking University | Lymphoma | Details | |
CD19 CARvac T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
CD19-7×19 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, Large B-Cell, Diffuse | Details | |
Anti CD19 chimeric antigen receptor T cell therapy (YaKe Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19/CD22 dual-target CAR-T (Yake biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CN-201 | CN-201 | Phase 2 Clinical | Tongrun Biomedicine (Shanghai) Co Ltd | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Lymphoma, B-Cell | Details | |
Bispecific CD19/22 CAR T cells | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Lymphoma, Non-Hodgkin; Lymphoma | Details | |
Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals) | CARCIK-CD19; CIK-CAR.CD19 | Phase 2 Clinical | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
TI-1007 | TI-1007 | Phase 1 Clinical | Tianjin Timmune Biotech Inc | Lymphoma, B-Cell | Details |
BinD-19 (Shenzhen BinDeBio) | BinD-19 | Phase 2 Clinical | Shenzhen Bindebio Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
BZ019 | BZ-019 | Phase 2 Clinical | Shanghai Cell Therapy Group Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma | Details |
Recombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical) | LNF-1904 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
Anti-CD19 CAR-T cell therapy (Juno Therapeutics) | Phase 1 Clinical | Juno Therapeutics Inc | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Ensomafusp alfa | RG-6076 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Details | |
Anbalcabtagene autoleucel | CRC-01 | Phase 2 Clinical | Curocell Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Details |
Azercabtagene zapreleucel | PBCAR-0191 | Phase 2 Clinical | Baxalta Incorporated | Hematologic Neoplasms; Leukemia, Lymphoid; Neoplasms; Lymphoma, Non-Hodgkin | Details |
GC019F | Phase 1 Clinical | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | ||
ALLO-501 | ALLO-501 | Cellectis Sa | Details | ||
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell | Details | |
CD19- and CD22 specific CAR (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Lymphoma | Details | |
U-01 | U-01 | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Leukemia; Leukemia, B-Cell | Details |
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) | Phase 1 Clinical | Henan Provincial Cancer Hospital | Lymphoma, B-Cell | Details | |
U-CART (Shanghai Bioray Laboratory Inc) | Phase 2 Clinical | Bioray Laboraytories Inc | Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
UCART-19 | S-68587; UCART-19 | Phase 1 Clinical | Cellectis Sa | Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
GC-502 | GC-502 | Phase 1 Clinical | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Leukemia, B-Cell | Details | |
Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | Phase 2 Clinical | The First Affiliated Hospital Of Nanchang University | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details | |
Anti-CD19 CAR-T cell therapy (Sinobioway) | Phase 2 Clinical | Sinobioway Biomedicine Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma | Details | |
Anti-CD19 CAR-T cell therapy (iCarTAB BioMed) | Phase 1 Clinical | Aikangd Biomedical Technology (Suzhou) Co Ltd | Leukemia; Lymphoma | Details | |
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) | CT-120 | Phase 2 Clinical | Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details | |
Humanized CD19 CAR-T cell therapy (Yake) | YK-C19 | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Murine CD19 CAR-T cell therapy (Yake) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Burkitt Lymphoma | Details | |
Anti-CD19 single-stranded antibody CAR T-cell therapy (Beijing Yongtai Rec Biotechnology) | Phase 1 Clinical | Beijing Yongtai Rec Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19 UCAR-T cell therapy (Shanghai Longyao Biotechnology) | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Leukemia, Myeloid, Acute | Details | |
CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech) | Phase 1 Clinical | Tianjin Timmune Biotech Inc | Leukemia | Details | |
Vadacabtagene leraleucel | 19-28z CAR T cells; 19-28z+ T cells; JCAR-015; JCAR-15; 19-28z-T-Cells | Phase 1 Clinical | Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Fred Hutchinson Cancer Research Center | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma | Details | |
ET-019002 | ET-019002 | Phase 1 Clinical | Eureka Therapeutics Inc | Lymphoma, B-Cell; Neoplasms | Details |
CC-97540 | CC-97540 | Phase 1 Clinical | Juno Therapeutics Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma | Details |
CAR-T-19 Cell Therapy (The General Hospital Of The People'S Liberation Army) | Phase 1 Clinical | Pla General Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology) | ssCART-19 | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) | Phase 1 Clinical | Fujian Medical University | Lymphoma, Large B-Cell, Diffuse | Details | |
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | POEMS Syndrome | Details | |
CLBR-001/SWI-019 | CLBR-001/SWI-019 | Phase 1 Clinical | Abbvie Inc, California Institute For Biomedical Research | Lymphoma, B-Cell | Details |
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) | CAR-20/19-T cells | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
ICT19G1 | ICT-19G1 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Humanized CAR19T2 T Cell therapy(Zhaotai Cell Bio-tech) | Details | ||||
CD19 CAR-T cell therapy (National University of Malaysia) | Phase 3 Clinical | National University Of Malaysia | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
19273-4SCAR | 19273-4SCAR | Phase 2 Clinical | Peking University | Lymphoma, B-Cell | Details |
TG-1801 | NI-1701; TG-1801 | Phase 1 Clinical | Novimmune Sa | Lymphoma, B-Cell | Details |
GNR-084 | GNR-084 | Phase 2 Clinical | Generium Pharmaceuticals, Iontas | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) | Phase 1 Clinical | The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CART-19 cells (Henan Hualong Biotechnology) | Phase 2 Clinical | Henan Hualong Biotechnology | Leukemia, Lymphoid | Details | |
19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells | TAK-940 | Phase 1 Clinical | Takeda | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Primary mediastinal B cell lymphoma; Burkitt Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Senl-1904A | Senl-1904A; Senl_1904A | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
CAR-T 19 cell therapy (University of Pennsylvania) | Phase 2 Clinical | University Of Pennsylvania | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-CAR-NK(JD Biotech) | JD-010; JD010 | Phase 1 Clinical | Beijing JD Biotech Co Ltd | Hematologic Neoplasms | Details |
GLPG-5101 | 19-CP-02; GLPG5101; 19CP02 | Phase 2 Clinical | CellPoint BV | Lymphoma, Non-Hodgkin | Details |
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Pancreatic Neoplasms; Lymphoma, Non-Hodgkin | Details | |
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell) | Phase 1 Clinical | Immune Cell Inc | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
CC-312 | CC-312 | Phase 1 Clinical | Details | ||
CAR-NK019(Second Affiliated Hospital, School of Medicine, Zhejiang University) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Lymphoma, Non-Hodgkin | Details | |
CTL-119 | CTL-119 | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Multiple Myeloma | Details |
KUR-502 CD19 CAR-NKT | CMD-502; KUR-502 | Phase 1 Clinical | Athenex Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
TAK-007 | TAK-007 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma, Non-Hodgkin | Details |
CD19-CD34 CAR transduced T cell therapy (Loyola University) | Phase 1 Clinical | Loyola University Chicago | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Autologous CD19 CAR+ EGFTt + T cells (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Leukemia, B-Cell | Details | |
Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering) | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital) | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Boston Children'S Hospital | Leukemia | Details | |
Allogeneic CD-19 CAR-T Cell Therapy | Phase 2 Clinical | Shenzhen University General Hospital | Leukemia; Lymphoma, B-Cell | Details | |
Anti-CD19-CAR γδT cells (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Leukemia; Lymphoma | Details | |
Obecabtagene autoleucel | AUTO1; Obe-cel; AUTO-1 | Phase 2 Clinical | University College London | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma | Details |
FT-819 | FT-8198; FT-819 | Phase 1 Clinical | Fate Therapeutics Inc | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19-CAR CMV-specific T-lymphocytes cell therapy (City Of Hope National Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details | |
LCAR-AIO | LCAR-AIO; VHH CAR-T | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University) | Phase 1 Clinical | Kunming Medical University | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Autologous CAR19 T lymphocytes Therapy | Phase 1 Clinical | Institute of Hematology and Blood Transfusion, Czech Republic | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
UCART019 | UCART-019 | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
KD-019 (Nanjing KAEDI Biotech) | KD-C19 (Nanjing KAEDI Biotech) | Phase 1 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Leukemia; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta) | Phase 2 Clinical | University Of Alberta | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
NKX-019 | NKX-019 | Phase 1 Clinical | Nkarta Inc | Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, Mantle-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Waldenstrom Macroglobulinemia; Lymphoma, Large-Cell, Anaplastic; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) | Phase 1 Clinical | Shanghai Jiaotong University, Shanghai General Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-CAR-DNT cells Therapy(Zhejiang Ruijiamei Biotechnologies Co Ltd) | Phase 1 Clinical | Zhejiang Ruijiamei Biotechnologies Co Ltd | Lymphoma, B-Cell | Details | |
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) | Phase 1 Clinical | Chengdu Yinhe Biomedicine Co Ltd, Beijing Marino Biotechnology Co Ltd | Lymphoma, B-Cell; Glioblastoma | Details | |
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy | GC-197 | Phase 2 Clinical | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) | Phase 2 Clinical | Kk Women'S And Children'S Hospital | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19 CAR engineered autologous T-cells Therapy(Sabz Biomedicals) | Phase 1 Clinical | Sabz Biomedicals | Leukemia, Biphenotypic, Acute | Details | |
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma, B-Cell; Neoplasm, Residual; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD19/CD22 CAR-T cell therapy (Shenzhen BinDeBio) | Phase 1 Clinical | Dehe Biotech Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR NK Cell therapy(Enricnk ) | Phase 1 Clinical | Nanjing Enricnk Biotech Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details | |
CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University, Suzhou University | Leukemia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-UCART | CD-19-UCART; CD19-UCART | Phase 1 Clinical | Bioray Laboraytories Inc | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
BRL-201 | BRL-201; PD1-19bbz; PD1-19bbz CAR-T | Phase 1 Clinical | Bioray Laboraytories Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
CAR-iNKT cells therapy (North Jiangsu People's Hospital) | Phase 1 Clinical | Affiliated Hospital Of Jiangsu University | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
ET-02 | ET-02 | Clinical | Edigene Inc | Lymphoma, B-Cell | Details |
1-A-46 | BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 | Phase 2 Clinical | Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
GC007g | GC-007G | Phase 2 Clinical | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
CAR-NK-CD19 Cell Therapy (Wuhan Union Hospital) | Phase 1 Clinical | Wuhan Union Hospital | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Autologous hematopoietic stem cell therapy (YaKe Biotechnology) | Phase 1 Clinical | Zhejiang University, Ningbo Yake Biotechnology Co Ltd | Lymphoma | Details | |
Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology) | Phase 3 Clinical | Wuhan Si'an Medical Technology Co Ltd, Xiangyang Central Hospital, Jingzhou Central Hospital, Wuhan Union Hospital, The First People'S Hospital Of Yuhang District | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
ET019003-T Cells | ET-019003 | Phase 1 Clinical | Wuhan Union Hospital, Eureka Therapeutics Inc | Leukemia; Lymphoma | Details |
ThisCART-19 | ThisCART-19; ThisCART19A; ThisCART19C; ThisCART19B | Phase 1 Clinical | Fundamenta Therapeutics Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, AIDS-Related; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma | Details |
IMPT-314 | IMPT-314 | Phase 1 Clinical | Lymphoma, B-Cell | Details | |
CLN-978 | CLN-978 | Phase 1 Clinical | Adimab LLC | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
SC-291 | SC-291 | Phase 1 Clinical | Sana Biotechnology Inc | Lymphoma, B-Cell | Details |
PIT-565 | PIT-565 | Phase 1 Clinical | Novartis Pharma Ag | Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | Details |
CD19 directed CAR T cell therapy (University of Colorado) | Phase 1 Clinical | University Of Colorado | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19- CD34t metabolically programmed CAR T-cell therapy (Medical University of South Carolina) | Phase 2 Clinical | Medical University Of South Carolina | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CARTHIAE-1 | CARTHIAE-1 | Phase 1 Clinical | Miltenyi Biotec Inc, Hospital Israelita Albert Einstein | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
CD19-Car T Cell Therapy(City Of Hope National Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center, National Cancer Institute | Lymphoma, B-Cell; Leukemia, Hairy Cell; Lymphomatoid Granulomatosis; Central Nervous System Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD19-CAR T cell therapy (Kecellitics Biotech) | Phase 2 Clinical | Kecellitics Biotech Company Ltd | Leukemia; Lymphoma, B-Cell | Details | |
YK-012 | YK012 | Phase 1 Clinical | Yikesite (Beijing) Pharmaceutical Technology Development Co Ltd | Lymphoma, B-Cell | Details |
Emfizatamab | GNC-038 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell | Details |
FT-596 | FT-596 | Phase 1 Clinical | Fate Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) | Phase 2 Clinical | Zhejiang University, Innovative Cellular Therapeutics Co Ltd, Kunming Medical University | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma | Details | |
VB-119 | Phase 2 Clinical | ValenzaBio Inc | Glomerulonephritis, Membranous; Nephrosis, Lipoid; Glomerulosclerosis, Focal Segmental | Details | |
RGV-004 | RGV-004 | Phase 1 Clinical | Hangzhou Rongu Biotechnology Co Ltd | Lymphoma, B-Cell | Details |
CAR-DC(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, B-Cell | Details | |
Anti-CD19/CD70 NK cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, Non-Hodgkin | Details | |
KITE-363 | KITE-363 | Phase 1 Clinical | Kite Pharma | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse | Details |
GC-012F | GC-012F | Phase 2 Clinical | Multiple Myeloma; Lymphoma, Non-Hodgkin | Details | |
SYNCAR-001 | SYNCAR-001 | Phase 1 Clinical | Synthekine Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Obexelimab | XmAb-5871; AMG-729 | Phase 3 Clinical | Xencor Inc | Immunoglobulin G4-Related Disease; Lupus Erythematosus, Systemic | Details |
CAR-CD19 T cell therapy | Phase 2 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Lymphoma, Non-Hodgkin | Details | |
AMG-562 | AMG-562 | Phase 1 Clinical | Amgen Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular | Details |
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) | HX-s001; YTS101; HX-s001/YTS101; HXYT-001 | Phase 1 Clinical | Beijing Qingyi Taike Pharmaceutical Technology Co Ltd, China Immunotech Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
CNTY-101 | CNTY-101 | Phase 1 Clinical | Century Therapeutics Llc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
CD19-CAR-T cell therapy (China Immunotech/Avalon Globocare) | AVA-001 (Avalon GloboCare); AVA-001 | Phase 1 Clinical | China Immunotech Co Ltd, Avalon Globocare Corp | Lymphoma, B-Cell | Details |
ALLO-501A | ALLO-501A | Phase 2 Clinical | Allogene Therapeutics Inc | Lymphoma, B-Cell | Details |
Metabolically Armed CD19 CAR-T cells(Leman Biotech) | Phase 1 Clinical | Anhui Provincial Hospital | Lymphoma, Large B-Cell, Diffuse | Details | |
CD19-t-haNK | Phase 1 Clinical | Nantkwest Inc, Immunitybio Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin | Details | |
CD19-CART(Hrain) | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
This web search service is supported by Google Inc.